Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective.

The exploration of coagulation led to identifying inflammation as a major factor in arterial disease throughout life. "Integrative molecular physiology" reflects our emerging understanding of how coagulation and inflammation integrate with one another, in both normal physiology and in pathophysiology. Our own responses to environmental challenge provide much of the damage that cumulatively results in chronic cardiovascular disease. Only by intervening in exquisitely precise ways can we hope to effectively and safely modify the course of lifelong chronic diseases, such as atherosclerosis.

[1]  K. Mann,et al.  The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial , 2004, Journal of Thrombosis and Thrombolysis.

[2]  S. Humphries,et al.  In the Elderly, Interleukin-6 Plasma Levels and the −174G>C Polymorphism Are Associated With the Development of Cardiovascular Disease , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[3]  G. Bernard,et al.  Activated protein C for severe sepsis. , 2002, The New England journal of medicine.

[4]  P. Savage,et al.  Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. , 2002, Diabetes.

[5]  B. Nordestgaard,et al.  Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. , 2002, Blood.

[6]  M. Margaglione,et al.  Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[7]  T. Lüscher,et al.  Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways , 2002, Circulation.

[8]  A. Folsom,et al.  A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. , 2002, Blood.

[9]  A. Arnold,et al.  No Association of Plasma Prothrombin Concentration or the G20210A Mutation with Incident Cardiovascular Disease , 2002, Thrombosis and Haemostasis.

[10]  R. Virmani,et al.  Traditional Risk Factors and the Incidence of Sudden Coronary Death With and Without Coronary Thrombosis in Blacks , 2002, Circulation.

[11]  K. Takeda,et al.  Thrombin Induces Interleukin-6 Expression Through the cAMP Response Element in Vascular Smooth Muscle Cells , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[12]  G. Lowe,et al.  Fibrin D-dimer, Markers of Coagulation Activation and the Risk of Major Ischaemic Heart Disease in the Caerphilly Study , 2001, Thrombosis and Haemostasis.

[13]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[14]  R. Tracy Is visceral adiposity the "enemy within"? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Runge,et al.  New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. , 2001, Circulation research.

[16]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[17]  J. Danesh,et al.  Fibrin D-Dimer and Coronary Heart Disease: Prospective Study and Meta-Analysis , 2001, Circulation.

[18]  V. Fuster,et al.  Coronary artery disease: pathogenesis and acute coronary syndromes. , 2001, The Mount Sinai journal of medicine, New York.

[19]  V. Salomaa,et al.  Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[21]  G. Hansson Immune mechanisms in atherosclerosis. , 1989, Arteriosclerosis, thrombosis, and vascular biology.

[22]  P. Wahl,et al.  Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. , 2000, American journal of epidemiology.

[23]  J. Meigs,et al.  Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. , 2000, American journal of epidemiology.

[24]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[25]  P. Pekala,et al.  Tumor necrosis factor-alpha-induced insulin resistance in adipocytes. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[26]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[27]  P. Sakkinen,et al.  Interleukin-6 exacerbates early atherosclerosis in mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  B. Sobel Coronary Artery Disease and Fibrinolysis: From the Blood to the Vessel Wall , 1999, Thrombosis and Haemostasis.

[29]  R. Tracy Epidemiological Evidence for Inflammation in Cardiovascular Disease , 1999, Thrombosis and Haemostasis.

[30]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[31]  P. Savage,et al.  The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[32]  G. Hotamisligil The role of TNFα and TNF receptors in obesity and insulin resistance , 1999 .

[33]  B. Sobel Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. , 1999, Circulation.

[34]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[35]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[36]  J. Yudkin Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? , 1999, Diabetes Care.

[37]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  G. Raghu,et al.  α-Thrombin Inhibits Interleukin-6-Induced Stat3 Signaling and gp130 Gene Expression in Primary Cultures of Human Lung Fibroblasts , 1999 .

[39]  A. Sharrett,et al.  Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[40]  L. Kuller,et al.  Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[41]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[42]  P. Morange,et al.  PAI-1, Obesity, and Insulin Resistance , 1999 .

[43]  I. Kullo,et al.  Vulnerable Plaque: Pathobiology and Clinical Implications , 1998, Annals of Internal Medicine.

[44]  F. Burzotta,et al.  The 4G/5G Polymorphism of PAI-1 Promoter Gene and the Risk of Myocardial Infarction: A Meta-analysis , 1998, Thrombosis and Haemostasis.

[45]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[46]  C. Thompson,et al.  Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. , 1998, Genes & development.

[47]  R. Bertina The prothrombin 20210 G to A variation and thrombosis , 1998, Current opinion in hematology.

[48]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[49]  V. Fuster,et al.  Atherothrombosis: mechanisms and clinical therapeutic approaches , 1998, Vascular medicine.

[50]  H. Lithell,et al.  Relation Between Plasma Tumor Necrosis Factor-α and Insulin Sensitivity in Elderly Men With Non–Insulin-Dependent Diabetes Mellitus , 1998 .

[51]  M. Cushman,et al.  Correlates of Antithrombin, Protein C, Protein S, and TFPI in a Healthy Elderly Cohort , 1998, Thrombosis and Haemostasis.

[52]  F. Rosendaal,et al.  Venous thrombosis--the interaction of genes and environment. , 1998, The New England journal of medicine.

[53]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[54]  D. Loskutoff,et al.  The adipocyte and hemostatic balance in obesity: studies of PAI-1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[55]  F. Neumann,et al.  Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[56]  D. Schneider,et al.  Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. , 1997, Circulation.

[57]  L. Kuller,et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[58]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[59]  D Kromhout,et al.  The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. , 1997, European heart journal.

[60]  T. Raghunathan,et al.  Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. , 1997, Blood.

[61]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[62]  R. Tracy Atherosclerosis, thrombosis and inflammation: a problem of linkage* , 1997 .

[63]  M. Alessi,et al.  Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. , 1996, Annals of medicine.

[64]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[65]  M. Nesheim,et al.  Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*) , 1995, The Journal of Biological Chemistry.

[66]  P. Edwards,et al.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. , 1995, Circulation.

[67]  M. Runge,et al.  Thrombin hypothesis of thrombus generation and vascular lesion formation. , 1995, The American journal of cardiology.

[68]  R. Califf,et al.  Acute Coronary Care In The Thrombolytic Era , 1995 .

[69]  R. Puri,et al.  Human Cytokines: Their Role in Disease and Therapy , 1995 .

[70]  R. Krauss,et al.  Multivariate analysis of the insulin resistance syndrome in women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[71]  P. Ridker,et al.  Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. , 1994, Circulation.

[72]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[73]  C. Esmon The protein C anticoagulant pathway. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[74]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[75]  P. Pilch,et al.  Insulin secretion and action and diabetes mellitus , 1992, Journal of cellular biochemistry.

[76]  C. Esmon,et al.  Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C , 1991, Thrombosis and Haemostasis.

[77]  T. Kooistra,et al.  Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2 , 1988, Thrombosis and Haemostasis.

[78]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[79]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[80]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[81]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[82]  M. C. Stone,et al.  Plasma fibrinogen--a major coronary risk factor. , 1985, The Journal of the Royal College of General Practitioners.

[83]  J. Verheijen,et al.  The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.

[84]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[85]  D. Ritchie,et al.  Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[86]  C. Mold,et al.  C-reactive protein and the acute phase response. , 1982, Advances in internal medicine.

[87]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[88]  S. Thompson,et al.  HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY , 1980, The Lancet.

[89]  H. Keen,et al.  Haemostatic variables associated with diabetes and its complications. , 1979, British medical journal.

[90]  Oxon Dm Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[91]  Maddocks Ac Letter: Sterilisation of cardiac bioptome. , 1974 .